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CASE REPORT
MPO-ANCA associated vasculitis 
with mononeuritis multiplex following influenza 
vaccination
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Abstract 
Background: Although influenza vaccines are generally safe and effective, a variety of autoimmune phenomena 
have been reported after vaccination over the past years, such as Guillain–Barre syndrome, rheumatoid arthritis, pem-
phigus vulgaris, psoriasis, giant cell arteritis and anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis 
(AAV).
Case report: We describe the case of a 67-year old man who presented with a myeloperoxidase-ANCA associated 
vasculitis with renal involvement and mononeuritis multiplex after seasonal influenza vaccination. He was initially 
treated with intravenous cyclophosphamide and high-dose prednisolone followed by maintenance treatment con-
sisting of azathioprine and prednisolone.
Conclusion: We hypothesize that seasonal influenza vaccination triggered a systemic immune response in a suscep-
tible patient to develop AAV with renal involvement and vasculitic neuropathy. In general, seasonal influenza vaccina-
tions are considered to be safe, however, clinicians should be aware of this rare phenomenon.
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Background
Seasonal influenza vaccination is widely used in the 
western world, particularly in the elderly population, 
chronically ill patients, immunocompromised subjects 
and health care workers to provide protection against 
influenza and its potential secondary complications. 
Although influenza vaccines are generally safe and effec-
tive, a variety of autoimmune phenomena have been 
reported after vaccination over the past years, such as 
Guillain–Barre syndrome, rheumatoid arthritis, pem-
phigus vulgaris, psoriasis, Henoch–Schönlein purpura, 
polymyalgia rheumatic, giant cell arteritis and anti-neu-
trophil cytoplasmic antibody (ANCA) associated vascu-
litis (AAV) [1–5]. AAV is a rare disease with an overall 
annual incidence of 13–20 cases per million individuals, 
with a peak incidence of only 65 per million/year in those 
aged 65–74 years [6, 7]. AAV is a small to medium vessel 
vasculitis, and comprises three syndromes: granuloma-
tosis with polyangiitis (GPA), microscopic polyangiitis 
(MPA) and eosinophilic granulomatosis with polyangiitis 
(EGPA) [8]. Here we describe a case of a patient present-
ing with AAV after influenza seasonal vaccination.
Case report
A 69-year-old Caucasian male patient, with no significant 
medical history, was evaluated in the IJsselland hospital. 
Since 8 weeks he had been suffering from fatigue, inter-
mittent fever and night sweats, weight loss (4  kg) and 
macroscopic haematuria. In addition, he complained of 
progressive muscle weakness in hands and legs as well as 
stiffness, numbness and tingling of both hands. He had 
gradually lost the ability to walk due to a lack of strength 
in his legs. Clinical symptoms started 2  weeks after 
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influenza vaccination. Over the past 3 years he received 
influenza vaccinations twice without any complications.
Physical examination revealed weakness in both his 
upper legs and arms and a reduced sense of feeling in his 
right arm. Also, both hands showed signs of muscular 
atrophy of the thumb muscles with flattening of the ball. 
The tendon reflexes at his legs were normal.
Blood tests showed raised levels of erythrocyte sedi-
mentation rate (ESR) and C-reactive protein (CRP), a 
mild normocytic anaemia, leukocytosis and normal renal 
function (creatinine 87  μmol/l) (Table  1). At admission 
the urinalysis demonstrated no active urinary sediment. 
Three weeks after hospital admission, serology revealed 
a positive perinuclear anti-neutrophil cytoplasmic anti-
body (pANCA) with positive myeloperoxidase (MPO)-
ANCA at a titer of 46 E/ml (reference < 3.5 E/ml). It was 
unknown if the patient was MPO-ANCA positive in the 
past. Imaging studies with computed tomography scan 
(CT scan) of chest and abdomen, magnetic resonance 
imaging (MRI) of head and neck, and positron emis-
sion tomography with 2-deoxy-2[fluorine-18]fluoro-
d-glucose with computed tomography (18F-FDG PET/
CT) revealed no abnormalities. No increase in cell count 
was seen during lumbar puncture. Cultures of cerebro-
spinal fluid, blood and urine as well as a tuberculin skin 
test and a quantiferon test were negative. Electromyogra-
phy (EMG) showed decreased compound muscle action 
potentials (cmap) of the peroneal nerves of both legs and 
the tibial nerve of the right leg. All the additional research 
was done before administration of prednisolone. During 
hospitalization kidney function deteriorated, with a max-
imum serum creatinine level of 178 µmol/l (upper limit 
of reference value 104 μmol/l). Three weeks after hospital 
admission, the urinalysis became deviant with red blood 
cells (2+) and protein (2+), dysmorphic erythrocyes and/
or red cell casts were not observed. Renal biopsy was 
conducted which revealed a small and medium-size vas-
culitis and tubulo-interstitial infiltration (Figs.  1 and 2). 
Three out of ten glomeruli showed glomerulosclerosis. 
Additional immunofluorescence with IgA, IgG, IgM, C3 
and C1q were negative.
Our patient was diagnosed having MPO-ANCA asso-
ciated vasculitis with involvement of kidneys and periph-
eral nerves one  month after admission to the hospital. 
Initial symptoms started two weeks after seasonal influ-
enza vaccination. Because of rapidly progressive disease 
therapy was initiated with high dosages of intravenously 
administered prednisolone (1000  mg) for three con-
secutive days followed by oral prednisolone in taper-
ing regimen, in combination with intravenous pulse 
cyclophosphamide (700  mg: 10  mg/kg adjusted for age 
and renal function) and trimethoprim/sulfamethoxa-
zole (480 mg daily) for Pneumocystis jiroveci pneumonia 
prophylaxis, according to the consensus regimen of the 
European vasculitis study group [9]. The cyclophospha-
mide treatment was continued for three months, result-
ing in remission of the disease process. Levels of ESR 
and CRP dropped and renal function stabilized (serum 
creatinine levels 140–150  µmol/l). He was discharged 
from the hospital to a rehabilitation centre for further 
recovery. Patient continued on azathioprine for another 
18 months. Remaining symptoms one year after initiation 
Table 1 Laboratory data of the patient on admission
Reference value
Hematology
 Hemoglobin (mmol/l) 7.6 8.5–11.0
 Mean corpuscular volume (fl) 81 80–100
 Hematocrit (l/l) 0.37 0.40–0.51
 Red blood cells 4.7 × 10E12/l 4.6–6.1 × 10E12/l
 White blood cells 20.6 × 10E9/l 4.2–9.1 × 10E9/l
 Neutrophils 17.0 × 10E9/l 1.5–9.0 × 10E9/l
 Lymphocytes (%) 7 20–50
 Monocytes (%) 9 2–10
 Eosinophils (%) 1 < 5
 Basophils (%) 0 < 2
 Platelets 397 × 10E9/l 165 × 10E9/l
Biochemistry/serology
 Creatinine (μmol/l) 87 59–104
 Sodium (mmol/l) 135 135–145
 Potassium (mmol/l) 3.8 3.5–5.0
 Blood urea nitrogen (mmol/l) 6.0 2.5–7.5
 C-reactive protein (mg/l) 163 < 5.0
 Erythrocyte sedimentation rate 
(mm/h)
103 < 15
 Albumin (g/l) 26 35–52
 Ferritin (μg/l) 710 25–250
 Vitamin B12 (pmol/l) 380 140–500
 Folic acid (nmol/l) 10.3 10.4–42.4
 Total bilirubin (μmol/l) 27 < 21
 Gamma glutamyl transferase (E/l) 240 < 55
 Alkaline phosphatase (E/l) 230 < 115
 Aspartate aminotransaminase (E/l) 28 < 35
 Alanine aminotransaminase (E/l) 34 < 45
 Lactate dehydrogenasis (E/l) 183 < 248
 Creatine kinase (E/l) 38 < 171
 MPO-ANCA (E/ml) 46 < 3.5
 PR3-ANCA (E/ml) 0.3 < 7.0
Urinary sediment
Protein 2+
Hemoglobine 2+
Red blood cells 4–10/HPF
Dysmorphic red blood cells (%) < 40
Page 3 of 5Eindhoven et al. Allergy Asthma Clin Immunol  (2017) 13:49 
of treatment consist of distal sensory loss of hands and 
feet and loss of fine motor skills of the hands.
Discussion
In this report, we described a patient with MPO-ANCA 
vasculitis with renal involvement and mononeuritis mul-
tiplex two  weeks after seasonal influenza vaccination. 
Since the patient showed overlapping sets of clinical fea-
tures it was difficult to diagnose the exact subtype of AAV 
[10, 11]. Currently, a handful of AAV cases have been 
reported in temporal association with influenza vaccina-
tion [12–17]. Recently, The Brighton Collaboration Vas-
culitis Working Group published a systematic literature 
review on adverse events following immunization (AEFI) 
suggesting an association between influenza vaccination 
and vasculitis, however no evidence is found to confirm 
this association yet [18]. The temporal relationship with 
the influenza vaccine could have been completely coinci-
dental in our case. Several other etiological factors, such 
as exposure to silica, viral or bacterial infections, medica-
tion and genetic susceptibility have also been correlated 
to AAV [19, 20].
Vasculitic neuropathy is characterized by a necrotiz-
ing vasculitis involving the small arterioles of peripheral 
nerves. Mononeuritis multiplex is a painful, asymmetri-
cal, asynchronous sensory and motor peripheral neurop-
athy involving isolated damage to at least two separate 
nerve areas. It can be distributed bilaterally, distally and 
proximally throughout the body, as we describe in our 
patient [21]. Hadden et al. reported several case reports 
with vasculitic neuropathy after influenza vaccination 
[22]. Mononeuritis multiplex was not proven histo-
pathologically in our patient. However, the progressive 
neurological impairment was highly suggestive of mon-
oneuritis multiplex, especially in combination with the 
results of the performed EMG as well as the histopatho-
logical proven renal vasculitis (level 2 evidence according 
to The Brighton Collaboration Vasculitic Peripheral Neu-
ropathy Working Group) [22].
The exact etiology of post-influenza vaccination vas-
culitis is unknown. Several possible underlying mecha-
nisms have been postulated, such as molecular mimicry, 
autoimmune syndrome induced by adjuvants (ASIA) 
and viral ribonucleic acid (RNA). In molecular mimicry, 
a microbial/foreign antigen shares structural similarities 
with self-antigens. Prolonged inflammatory responses 
to these foreign antigens can therefore induce autoim-
munity syndromes in predisposed individuals [23–25]. A 
second possible mechanism is ASIA. Adding an adjuvant 
to a vaccine antigen leads to several advantages, includ-
ing dose sparing and the introduction of a more rapid, 
broader and strong immune response. However, disad-
vantages of these adjuvants have been described as well. 
The pathogenesis of the ASIA syndrome is founded on 
the hypothesis that an exposure to an adjuvant may trig-
ger the development of an autoimmune disease [26, 27]. 
The influenza vaccination our patient received was the 
third vaccination in three  years. The first two  years he 
had no complications after the vaccination. In 2011, his 
first influenza vaccine contained 4 viral types: A/Califor-
nia/7/09 A (H1N1), A/Perth/16/2009 (H3N2), A/Victo-
ria/2010/2009 and B/Brisbane/60/08. In 2012, his second 
influenza vaccine contained the same California type, 
but also contained B/Victoria/361/2011 (H3N2) and B/
Wisconsin/1/2010. His third vaccination consisted of the 
same California and Victoria types and of B/Massachus-
sets/02/2012. Unfortunately, we were not able to obtain 
information on whether these vaccines were adjuvanted 
Fig. 1 Light microscopy imaging of the renal biopsy demonstrating 
a small vessel vasculitis. Original magnification ×400, using Haema-
toxylin–eosin stain
Fig. 2 Light microscopy imaging of the renal biopsy demonstrat-
ing a medium sized vasculitis. Original magnification ×100, using 
Haematoxylin–eosin stain
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or not. According to the ASIA criteria defined by Alijo-
tas-Reig, our patient met three major criteria, including 
exposure to an external stimulus, minimum latency time 
of days and muscle weakness [28]. Recently, another pos-
sible mechanism has been proposed regarding influenza 
vaccines containing viral RNA which may increase the 
production of Proteinase 3 (PR3-ANCA) and thus fur-
ther contribute to the development of AAV following 
influenza vaccination [17].
Several clinical trials have investigated the relapse rate 
of AAV after influenza vaccination. Overall, influenza 
vaccination does not seem to increase the relapse rate in 
patients with pre-existent AAV in remission [29, 30]. Fur-
thermore, the disease free survival was lower in patients 
not vaccinated [30]. A recent report showed no changes 
in auto-antibody levels after influenza vaccination in a 
small group of healthy individuals [29]. However, one 
study found silent auto-antibody formation after influenza 
vaccination in healthy individuals, but this did not reach 
statistical significance and none of the participants had 
clinical symptoms of systemic autoimmune disease [31].
In this report we described another case suggesting a 
temporal relationship between influenza vaccination 
and AAV with mononeuritis multiplex. However, exist-
ing literature does not support a causative link between 
vaccination and vasculitis yet. Further research is needed 
to evaluate this potential causal relationship, especially 
given the extent of influenza vaccinations administered 
to the peak age incidence population on an annual basis. 
In general, seasonal influenza vaccinations are consid-
ered to be safe, however, clinicians should be aware of 
this rare phenomenon.
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